PMID- 36626292
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230430
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 53
IP  - 5
DP  - 2023 May
TI  - Factors associated with liver injury and prognosis in advanced cancer patients 
      treated with immune checkpoint inhibitors.
PG  - 450-459
LID - 10.1111/hepr.13878 [doi]
AB  - AIM: The use of immune checkpoint inhibitors (ICIs) has increased remarkably, and 
      immune-related adverse events (irAEs) have also increased. This study aimed to 
      identify factors associated with immune-related liver injury (irLI), and the 
      relationship between the grades of irLI and overall survival (OS) in patients 
      treated with ICIs. METHODS: A total of 571 patients who had been treated for 
      advanced malignancies with ICIs between January 2015 and March 2022 were 
      retrospectively recruited. The presence of liver injury was determined by the 
      aspartate aminotransferase and alanine aminotransferase elevation. The irLI 
      grading was based on Common Terminology Criteria for Adverse Events version 5.0. 
      RESULTS: A total of 50 (8.8%) patients had grade >/=2 irLI and 24 (4.2%) had grade 
      >/=3 irLI. Treatment with anti-cytotoxic T-lymphocyte-associated protein-4 agents 
      and baseline grade 1 aspartate aminotransferase/alanine aminotransferase 
      elevation were independent predictive factors of grade >/=2 irLI. Treatment with 
      anti-cytotoxic T-lymphocyte-associated protein-4 was the only independent 
      predictive factor of grade >/=3 irLI. The median OS for patients who experienced 
      any irAEs was significantly longer than of those without irAEs (hazard ratio 
      0.503, 95% CI 0.398-0.636, p < 0.001). The median OS in patients with grade >/=2 
      irLI was significantly longer (HR 0.570, 95% CI 0.387-0.838, p = 0.022). There 
      was no significant difference between the median OS in patients with grade >/=3 
      irLI and the others (p = 0.11). CONCLUSION: The incidence of irLI was 
      significantly higher in patients treated with anti-cytotoxic 
      T-lymphocyte-associated protein-4 agents. Even in patients with pre-existing 
      grade 1 aspartate aminotransferase/alanine aminotransferase elevation, 
      appropriate follow-up and control of the irLI can improve the prognosis.
CI  - (c) 2023 Japan Society of Hepatology.
FAU - Kaneko, Shun
AU  - Kaneko S
AUID- ORCID: 0000-0003-2660-6580
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Asahina, Yasuhiro
AU  - Asahina Y
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
AD  - Department of Liver Disease Control, Tokyo Medical and Dental University, Tokyo, 
      Japan.
FAU - Nakagawa, Mina
AU  - Nakagawa M
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Murakawa, Miyako
AU  - Murakawa M
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Miyazaki, Yasunari
AU  - Miyazaki Y
AD  - Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, 
      Japan.
FAU - Asakage, Takahiro
AU  - Asakage T
AD  - Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, 
      Japan.
FAU - Fukuda, Shohei
AU  - Fukuda S
AD  - Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.
FAU - Namiki, Takeshi
AU  - Namiki T
AD  - Department of Dermatology, Tokyo Medical and Dental University, Tokyo, Japan.
FAU - Kano, Yoshihito
AU  - Kano Y
AD  - Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, 
      Tokyo Medical and Dental University, Tokyo, Japan.
FAU - Nagata, Masashi
AU  - Nagata M
AD  - Department of Pharmacy, Tokyo Medical and Dental University, Tokyo, Japan.
FAU - Tsuchiya, Jun
AU  - Tsuchiya J
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Miyoshi, Masato
AU  - Miyoshi M
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Kitahata-Kawai, Fukiko
AU  - Kitahata-Kawai F
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Nitta, Sayuri
AU  - Nitta S
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Itsui, Yasuhiro
AU  - Itsui Y
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Kakinuma, Sei
AU  - Kakinuma S
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Okamoto, Ryuichi
AU  - Okamoto R
AD  - Department of Gastroenterology and Hepatology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
LA  - eng
GR  - None/
PT  - Journal Article
DEP - 20230127
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - cytotoxic T-lymphocyte-associated protein-4
OT  - immune checkpoint inhibitors
OT  - immune-related adverse events
OT  - liver injury
OT  - programmed death receptor-1
OT  - programmed death-ligand 1
EDAT- 2023/01/11 06:00
MHDA- 2023/01/11 06:01
CRDT- 2023/01/10 12:44
PHST- 2022/12/21 00:00 [revised]
PHST- 2022/11/23 00:00 [received]
PHST- 2023/01/05 00:00 [accepted]
PHST- 2023/01/11 06:01 [medline]
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/01/10 12:44 [entrez]
AID - 10.1111/hepr.13878 [doi]
PST - ppublish
SO  - Hepatol Res. 2023 May;53(5):450-459. doi: 10.1111/hepr.13878. Epub 2023 Jan 27.